#Sweden #Stockholm #Sobi #shares #Incentive Programs

Sobi Board Authorizes Share Repurchase

On July 15, 2025, the Board of Directors for Swedish Orphan Biovitrum AB, commonly known as Sobi, announced a significant decision during their Annual General Meeting (AGM). The shareholders convened on May 8, 2025, to address the future direction of the company, particularly in relation to its incentive compensation programs.

The board resolved to initiate a share repurchase program aimed at fulfilling the company’s commitments under these long-term incentive plans. The resolution permits an issue of up to 1,412,788 redeemable and convertible class C shares, demonstrating Sobi's commitment to enhancing shareholder value and cultivating investor confidence.

Details of the Share Repurchase

The AGM's discussion culminated in authorizing the board to buy back all outstanding class C shares through an offer directed towards all existing holders. Such a buyback can be executed over one or multiple occasions before the next Annual General Meeting set for 2026. The shares will be repurchased at a price ranging from 100% to 105% of their quotient value, ensuring minimal risk to investors.

The Board recently decided to activate this authorization and plans to repurchase the class C shares at 100% of the quotient value, estimated to be around SEK 0.55 per share. The timeframe for this buyback spans from July 16 to November 7, 2025. As it stands, Sobi currently holds 11,377,680 of its common shares, but lacks class C shares. Following the repurchase, Sobi anticipates converting these class C shares into common shares, increasing their total common shares to 12,790,468.

Sobi's Mission and Performance

Sobi is a leading global biopharmaceutical company dedicated to transforming the lives of individuals affected by rare diseases. With a workforce of approximately 1,900 employees globally, the company's operations extend across Europe, North America, the Middle East, Asia, and Australia. In 2024, Sobi realized an impressive revenue of SEK 26 billion, solidifying its position in the biopharma sector.

As a publicly traded entity, Sobi’s shares (STOSOBI) are listed on Nasdaq Stockholm, reflecting its commitment to transparency and active engagement with shareholders. For additional insights about Sobi, stakeholders can refer to their official website at sobi.com or connect via their LinkedIn profile.

Conclusion

The authorization for a share buyback signifies Sobi’s proactive approach to maintaining investor relations and ensuring strategic growth amid changing market dynamics. Both current and potential investors can look forward to further developments as the buyback takes place, reflecting Sobi's dedication to creating long-term value while participating in future growth initiatives.